SAB Biotherapeutics annual operating margin
2020
2021
2022
2023
2024
SAB Biotherapeutics's operating margin was −3,244.87% for fiscal 2024.
View full SAB Biotherapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −3,244.87% | −1544.32 pp |
| 2023 | 2023-12-31 | −1,700.56% | −1579.58 pp |
| 2022 | 2022-12-31 | −120.97% | −98.97 pp |
| 2021 | 2021-12-31 | −22.00% | −59.22 pp |
| 2020 | 2020-12-31 | 37.22% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2024 | 2024-09-30 | −4,297.90% | −3877.90 pp |
| Q2 2024 | 2024-06-30 | −3,876.95% | +3696.44 pp |
| Q1 2024 | 2024-03-31 | −1,205.90% | +67.89 pp |
| Q4 2023 | 2023-12-31 | −6,187.90% | −5824.16 pp |
| Q3 2023 | 2023-09-30 | −420.00% | −202.51 pp |
| Q2 2023 | 2023-06-30 | −7,573.40% | −7470.37 pp |
| Q1 2023 | 2023-03-31 | −1,273.79% | −1216.96 pp |
| Q4 2022 | 2022-12-31 | −363.74% | −297.33 pp |
| Q3 2022 | 2022-09-30 | −217.49% | −190.31 pp |
| Q2 2022 | 2022-06-30 | −103.03% | −87.26 pp |
| Q1 2022 | 2022-03-31 | −56.83% | −61.64 pp |
| Q4 2021 | 2021-12-31 | −66.41% | — |
| Q3 2021 | 2021-09-30 | −27.18% | — |
| Q2 2021 | 2021-06-30 | −15.77% | — |
| Q1 2021 | 2021-03-31 | 4.81% | — |
Across the available reported history, SAB Biotherapeutics's operating margin decreased from −1,700.56% to −3,244.87%, a change of −1544.32 percentage points. The latest reported quarter, Q3 2024, shows −4,297.90%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics filings at SEC.gov ↗